Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Semaglutide (Wegovy) significantly cut BMI in children aged 6–11 with obesity, according to phase 3 STEP Young trial data presented at ObesityWeek. Kids on the drug saw a 13.5% BMI decrease vs. a 2.7% gain in the placebo group at 68 weeks, with cardiometabolic improvements and no new safety signals — raising the possibility of expanding treatment to younger children.
Wegovy shrinks BMI in kids as young as 6 — and the results are hard to ignore
The phase 3 STEP Young trial has delivered striking results: once-weekly injectable semaglutide (Wegovy) produced substantial BMI reductions in children aged 6–11 with obesity, with no new safety concerns. Presented at ObesityWeek and simultaneously published in The New England Journal of Medicine, the 2-year randomized controlled trial is the longest of its kind in this age group.
Children on semaglutide saw a 13.5% BMI decrease at 68 weeks, compared to a 2.7% increase in the placebo group. Beyond BMI, the drug improved waist circumference, blood pressure, HbA1c, and triglycerides — and 93% of kids with prediabetes at baseline achieved normal HbA1c levels by week 68.
By the Numbers:
Why it matters: No GLP-1 receptor agonist is currently approved in the U.S. for children under 12. These findings could support a regulatory push to expand semaglutide's indication to younger kids — and signal a broader shift toward earlier, pharmacological intervention in childhood obesity.